BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Schneider PM, Baldus SE, Metzger R, Kocher M, Bongartz R, Bollschweiler E, Schaefer H, Thiele J, Dienes HP, Mueller RP. Histomorphologic tumor regression and lymph node metastases determine prognosis following neoadjuvant radiochemotherapy for esophageal cancer: implications for response classification. Ann Surg. 2005;242:684-692. [PMID: 16244542 DOI: 10.1097/01.sla.0000186170.38348.7b] [Cited by in Crossref: 256] [Cited by in F6Publishing: 206] [Article Influence: 16.0] [Reference Citation Analysis]
Number Citing Articles
1 Bludau M, Hölscher AH, Vallböhmer D, Gutschow C, Schröder W. Ischemic conditioning of the gastric conduit prior to esophagectomy improves mucosal oxygen saturation. Ann Thorac Surg 2010;90:1121-6. [PMID: 20868800 DOI: 10.1016/j.athoracsur.2010.06.003] [Cited by in Crossref: 29] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
2 Liao Z, Cox JD, Komaki R. Radiochemotherapy of esophageal cancer. J Thorac Oncol. 2007;2:553-568. [PMID: 17545853 DOI: 10.1097/01.JTO.0000275339.62831.5e] [Cited by in Crossref: 25] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
3 Li Y, Huang HC, Chen LQ, Xu LY, Li EM, Zhang JJ. Predictive biomarkers for response of esophageal cancer to chemo(radio)therapy: A systematic review and meta-analysis. Surg Oncol 2017;26:460-72. [PMID: 29113666 DOI: 10.1016/j.suronc.2017.09.003] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
4 Schiffmann LM, Göbel H, Löser H, Schorn F, Werthenbach JP, Fuchs HF, Plum PS, Bludau M, Zander T, Schröder W, Bruns CJ, Kashkar H, Quaas A, Gebauer F. Elevated X-linked inhibitor of apoptosis protein (XIAP) expression uncovers detrimental prognosis in subgroups of neoadjuvant treated and T-cell rich esophageal adenocarcinoma. BMC Cancer 2019;19:531. [PMID: 31151416 DOI: 10.1186/s12885-019-5722-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
5 Yang PW, Hsieh CY, Kuo FT, Huang PM, Hsu HH, Kuo SW, Chen JS, Lee JM. The survival impact of XPA and XPC genetic polymorphisms on patients with esophageal squamous cell carcinoma. Ann Surg Oncol 2013;20:562-71. [PMID: 22941172 DOI: 10.1245/s10434-012-2622-x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
6 Yuan H, Tong DK, Vardhanabhuti V, Law SY, Chiu KW, Khong P. PET/CT in the evaluation of treatment response to neoadjuvant chemoradiotherapy and prognostication in patients with locally advanced esophageal squamous cell carcinoma. Nuclear Medicine Communications 2016;37:947-55. [DOI: 10.1097/mnm.0000000000000527] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
7 Raman V, Jawitz OK, Voigt SL, Yang CJ, D'Amico TA, Harpole DH Jr. The Role of Adjuvant Therapy in Patients With Margin-Positive (R1) Esophagectomy: A National Analysis. J Surg Res 2020;249:82-90. [PMID: 31926400 DOI: 10.1016/j.jss.2019.11.035] [Reference Citation Analysis]
8 Pera M, Gallego R, Montagut C, Martín-richard M, Iglesias M, Conill C, Reig A, Balagué C, Pétriz L, Momblan D, Bellmunt J, Maurel J. Phase II trial of preoperative chemoradiotherapy with oxaliplatin, cisplatin, and 5-FU in locally advanced esophageal and gastric cancer. Annals of Oncology 2012;23:664-70. [DOI: 10.1093/annonc/mdr291] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.4] [Reference Citation Analysis]
9 Shapiro J, van Hagen P, Lingsma HF, Wijnhoven BP, Biermann K, ten Kate FJ, Steyerberg EW, van der Gaast A, van Lanschot JJ; CROSS Study Group. Prolonged time to surgery after neoadjuvant chemoradiotherapy increases histopathological response without affecting survival in patients with esophageal or junctional cancer. Ann Surg. 2014;260:807-813; discussion 813-814. [PMID: 25379852 DOI: 10.1097/sla.0000000000000966] [Cited by in Crossref: 43] [Cited by in F6Publishing: 12] [Article Influence: 7.2] [Reference Citation Analysis]
10 Motoi F, Rikiyama T, Katayose Y, Egawa S, Unno M. Retrospective Evaluation of the Influence of Postoperative Tumor Marker Status on Survival and Patterns of Recurrence After Surgery for Pancreatic Cancer Based on RECIST Guidelines. Ann Surg Oncol 2011;18:371-9. [DOI: 10.1245/s10434-010-1311-x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 2.5] [Reference Citation Analysis]
11 Hölscher AH, Bollschweiler E, Bogoevski D, Schmidt H, Semrau R, Izbicki JR. Prognostic impact of neoadjuvant chemoradiation in cT3 oesophageal cancer - A propensity score matched analysis. Eur J Cancer 2014;50:2950-7. [PMID: 25307749 DOI: 10.1016/j.ejca.2014.08.020] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 3.9] [Reference Citation Analysis]
12 Zhang C, Zhang Z, Zhang G, Xue L, Yang H, Luo Y, Zheng X, Zhang Y, Yuan Y, Lei R, Yang Z, Zheng B, Zhang Z, Wang L, Che Y, Wang S, Wang F, Fang L, Zeng Q, Li J, Gao S, Xue Q, Sun N, He J. A three-lncRNA signature of pretreatment biopsies predicts pathological response and outcome in esophageal squamous cell carcinoma with neoadjuvant chemoradiotherapy. Clin Transl Med 2020;10:e156. [PMID: 32898328 DOI: 10.1002/ctm2.156] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
13 van Meerten E, van der Gaast A, Tilanus H, Poley J, Muller K, van Dekken H. Pathological analysis after neoadjuvant chemoradiotherapy for esophageal carcinoma: The rotterdam experience. J Surg Oncol 2009;100:32-7. [DOI: 10.1002/jso.21295] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.6] [Reference Citation Analysis]
14 Klevebro F, Tsekrekos A, Low D, Lundell L, Vieth M, Detlefsen S. Relevant issues in tumor regression grading of histopathological response to neoadjuvant treatment in adenocarcinomas of the esophagus and gastroesophageal junction. Dis Esophagus 2020;33:doaa005. [PMID: 32141500 DOI: 10.1093/dote/doaa005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
15 Odenthal M, Bollschweiler E, Grimminger P, Schröder W, Brabender J, Drebber U, Hölscher A, Metzger R, Vallböhmer D. MicroRNA profiling in locally advanced esophageal cancer indicates a high potential of miR-192 in prediction of multimodality therapy response: MicroRNA profiling in esophageal cancer. Int J Cancer 2013;133:2454-63. [DOI: 10.1002/ijc.28253] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 3.1] [Reference Citation Analysis]
16 Díaz-González JA, Rodríguez J, Hernández-Lizoain JL, Ciérvide R, Gaztañaga M, San Miguel I, Arbea L, Aristu JJ, Chopitea A, Martínez-Regueira F, Valentí V, García-Foncillas J, Martínez-Monge R, Sola JJ. Patterns of response after preoperative treatment in gastric cancer. Int J Radiat Oncol Biol Phys 2011;80:698-704. [PMID: 20656414 DOI: 10.1016/j.ijrobp.2010.02.054] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
17 Schröder W, Vallböhmer D, Bludau M, Banczyk A, Gutschow C, Hölscher AH. The resection of the azygos vein--necessary or redundant extension of transthoracic esophagectomy? J Gastrointest Surg 2008;12:1163-7. [PMID: 18278537 DOI: 10.1007/s11605-008-0487-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
18 Cho HJ, Kim Y, Kim HR, Kim DK, Park S, Kim JH, Kim S. Oncologic Outcomes According to Remnant Lymph Node Metastases in Pathologic T0 (ypT0) Esophageal Squamous Cell Carcinoma Following Prospective Neoadjuvant Therapy and Surgery. Ann Surg Oncol 2015;22:1851-7. [DOI: 10.1245/s10434-014-4195-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
19 Mansour JC, Schwarz RE. Pathologic Response to Preoperative Therapy: Does It Mean What We Think It Means? Ann Surg Oncol 2009;16:1465-79. [DOI: 10.1245/s10434-009-0374-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
20 Hölscher AH, Drebber U, Schmidt H, Bollschweiler E. Prognostic classification of histopathologic response to neoadjuvant therapy in esophageal adenocarcinoma. Ann Surg 2014;260:779-84; discussion 784-5. [PMID: 25379849 DOI: 10.1097/SLA.0000000000000964] [Cited by in Crossref: 43] [Cited by in F6Publishing: 15] [Article Influence: 7.2] [Reference Citation Analysis]
21 Hoffmann AC, Vallböhmer D, Prenzel K, Metzger R, Heitmann M, Neiss S, Ling F, Hölscher AH, Schneider PM, Brabender J. Methylated DAPK and APC promoter DNA detection in peripheral blood is significantly associated with apparent residual tumor and outcome. J Cancer Res Clin Oncol. 2009;135:1231-1237. [PMID: 19259700 DOI: 10.1007/s00432-009-0564-x] [Cited by in Crossref: 38] [Cited by in F6Publishing: 26] [Article Influence: 3.2] [Reference Citation Analysis]
22 Vallböhmer D, Hölscher AH, DeMeester S, DeMeester T, Salo J, Peters J, Lerut T, Swisher SG, Schröder W, Bollschweiler E. A multicenter study of survival after neoadjuvant radiotherapy/chemotherapy and esophagectomy for ypT0N0M0R0 esophageal cancer. Ann Surg. 2010;252:744-749. [PMID: 21037429 DOI: 10.1097/sla.0b013e3181fb8dde] [Cited by in Crossref: 108] [Cited by in F6Publishing: 32] [Article Influence: 9.8] [Reference Citation Analysis]
23 Langer R, Becker K, Zlobec I, Gertler R, Sisic L, Büchler M, Lordick F, Slotta-Huspenina J, Weichert W, Höfler H, Feith M, Ott K. A multifactorial histopathologic score for the prediction of prognosis of resected esophageal adenocarcinomas after neoadjuvant chemotherapy. Ann Surg Oncol 2014;21:915-21. [PMID: 24281419 DOI: 10.1245/s10434-013-3410-y] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]
24 Grimminger PP, Brabender J, Warnecke-Eberz U, Narumiya K, Wandhöfer C, Drebber U, Bollschweiler E, Hölscher AH, Metzger R, Vallböhmer D. XRCC1 gene polymorphism for prediction of response and prognosis in the multimodality therapy of patients with locally advanced rectal cancer. J Surg Res 2010;164:e61-6. [PMID: 20863523 DOI: 10.1016/j.jss.2010.08.002] [Cited by in Crossref: 16] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
25 Chuong MD, Frakes JM, Figura N, Hoffe SE, Shridhar R, Mellon EA, Hodul PJ, Malafa MP, Springett GM, Centeno BA. Histopathologic tumor response after induction chemotherapy and stereotactic body radiation therapy for borderline resectable pancreatic cancer. J Gastrointest Oncol 2016;7:221-7. [PMID: 27034789 DOI: 10.3978/j.issn.2078-6891.2015.075] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
26 Reynolds JV, Muldoon C, Hollywood D, Ravi N, Rowley S, O'Byrne K, Kennedy J, Murphy TJ. Long-term outcomes following neoadjuvant chemoradiotherapy for esophageal cancer. Ann Surg 2007;245:707-16. [PMID: 17457163 DOI: 10.1097/01.sla.0000254367.15810.38] [Cited by in Crossref: 118] [Cited by in F6Publishing: 96] [Article Influence: 8.4] [Reference Citation Analysis]
27 Siddiqui MR, Bhoday J, Battersby NJ, Chand M, West NP, Abulafi AM, Tekkis PP, Brown G. Defining response to radiotherapy in rectal cancer using magnetic resonance imaging and histopathological scales. World J Gastroenterol 2016;22:8414-34. [PMID: 27729748 DOI: 10.3748/wjg.v22.i37.8414] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 13] [Article Influence: 5.5] [Reference Citation Analysis]
28 Qian D, Wang Y, Zhao G, Cao F, Er P, Chen X, Cheng J, Zhang W, Li X, Zhang B, Guan Y, Zhou D, Wang J, Jiang H, Yu Z, Yuan Z, Wang P, Pang Q. Tumor Remission and Tumor-Infiltrating Lymphocytes During Chemoradiation Therapy: Predictive and Prognostic Markers in Locally Advanced Esophageal Squamous Cell Carcinoma. Int J Radiat Oncol Biol Phys 2019;105:319-28. [PMID: 31228553 DOI: 10.1016/j.ijrobp.2019.06.079] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
29 Visser E, van Rossum PSN, Ruurda JP, van Hillegersberg R. Impact of Lymph Node Yield on Overall Survival in Patients Treated With Neoadjuvant Chemoradiotherapy Followed by Esophagectomy for Cancer: A Population-based Cohort Study in the Netherlands. Ann Surg 2017;266:863-9. [PMID: 28742691 DOI: 10.1097/SLA.0000000000002389] [Cited by in Crossref: 25] [Cited by in F6Publishing: 10] [Article Influence: 6.3] [Reference Citation Analysis]
30 Ott K, Rachakonda PS, Panzram B, Keller G, Lordick F, Becker K, Langer R, Buechler M, Hemminki K, Kumar R. DNA repair gene and MTHFR gene polymorphisms as prognostic markers in locally advanced adenocarcinoma of the esophagus or stomach treated with cisplatin and 5-fluorouracil-based neoadjuvant chemotherapy. Ann Surg Oncol. 2011;18:2688-2698. [PMID: 21347786 DOI: 10.1245/s10434-011-1601-y] [Cited by in Crossref: 41] [Cited by in F6Publishing: 33] [Article Influence: 4.1] [Reference Citation Analysis]
31 Li Z, Wang Y, Shan F, Ying X, Wu Z, Xue K, Miao R, Zhang Y, Ji J. ypTNM staging after neoadjuvant chemotherapy in the Chinese gastric cancer population: an evaluation on the prognostic value of the AJCC eighth edition cancer staging system. Gastric Cancer 2018;21:977-87. [PMID: 29748876 DOI: 10.1007/s10120-018-0830-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
32 Leers JM, Ayazi S, Hagen JA, Terterov S, Klipfel N, Oezcelik A, Abate E, Lipham JC, DeMeester SR, Banki F. Survival in lymph node negative adenocarcinoma of the esophagus after R0 resection with and without neoadjuvant therapy: evidence for downstaging of N status. J Am Coll Surg. 2009;208:553-556. [PMID: 19476789 DOI: 10.1016/j.jamcollsurg.2009.01.017] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
33 Konno-kumagai T, Fujishima F, Nakamura Y, Nakano T, Nagai T, Kamei T, Sasano H. Programmed death-1 ligands and tumor infiltrating T lymphocytes in primary and lymph node metastasis of esophageal cancer patients. Diseases of the Esophagus 2018;32. [DOI: 10.1093/dote/doy063] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
34 Wong C, Law S. Predictive factors in the evaluation of treatment response to neoadjuvant chemoradiotherapy in patients with advanced esophageal squamous cell cancer. J Thorac Dis 2017;9:S773-80. [PMID: 28815073 DOI: 10.21037/jtd.2017.04.29] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
35 Nagai Y, Yoshida N, Baba Y, Harada K, Imai K, Iwatsuki M, Karashima R, Koga Y, Nomoto D, Okadome K, Ishimoto T, Imamura Y, Watanabe M, Baba H. Clinical significance of evaluating endoscopic response to neoadjuvant chemotherapy in esophageal squamous cell carcinoma. Digestive Endoscopy 2019;32:39-48. [DOI: 10.1111/den.13449] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
36 Chao Y, Chuang W, Chang H, Tseng C, Yeh C, Liu Y. Prognosis of patients with esophageal squamous cell carcinoma who achieve major histopathological response after neoadjuvant chemoradiotherapy. European Journal of Surgical Oncology (EJSO) 2017;43:234-9. [DOI: 10.1016/j.ejso.2016.05.036] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
37 Karamitopoulou E, Thies S, Zlobec I, Ott K, Feith M, Slotta-Huspenina J, Lordick F, Becker K, Langer R. Assessment of tumor regression of esophageal adenocarcinomas after neoadjuvant chemotherapy: comparison of 2 commonly used scoring approaches. Am J Surg Pathol 2014;38:1551-6. [PMID: 25140894 DOI: 10.1097/PAS.0000000000000255] [Cited by in Crossref: 27] [Cited by in F6Publishing: 11] [Article Influence: 3.9] [Reference Citation Analysis]
38 Alakus H, Warnecke-Eberz U, Bollschweiler E, Mönig SP, Vallböhmer D, Brabender J, Drebber U, Baldus SE, Riemann K, Siffert W, Hölscher AH, Metzger R. GNAS1 T393C polymorphism is associated with histopathological response to neoadjuvant radiochemotherapy in esophageal cancer. Pharmacogenomics J 2009;9:202-7. [PMID: 19274060 DOI: 10.1038/tpj.2009.5] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
39 Oguma J, Ozawa S, Koyanagi K, Kazuno A, Yamamoto M, Ninomiya Y, Yatabe K. Prognostic significance of pathological tumor response and residual nodal metastasis in patients with esophageal squamous cell carcinoma after neoadjuvant chemotherapy followed by surgery. Esophagus 2019;16:395-401. [DOI: 10.1007/s10388-019-00679-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
40 van Heijl M, Phoa S, van Berge Henegouwen M, Omloo J, Mearadji B, Sloof G, Bossuyt P, Hulshof M, Richel D, Bergman J, ten Kate F, Stoker J, van Lanschot J. Accuracy and reproducibility of 3D-CT measurements for early response assessment of chemoradiotherapy in patients with oesophageal cancer. European Journal of Surgical Oncology (EJSO) 2011;37:1064-71. [DOI: 10.1016/j.ejso.2011.09.004] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 2.6] [Reference Citation Analysis]
41 Zhou J, Shen J, Seifer BJ, Jiang S, Wang J, Xiong H, Xie L, Wang L, Sui X. Approaches and genetic determinants in predicting response to neoadjuvant chemotherapy in locally advanced gastric cancer. Oncotarget 2017;8:30477-94. [PMID: 27802185 DOI: 10.18632/oncotarget.12955] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
42 Bollschweiler E, Hölscher AH, Schmidt M, Warnecke-Eberz U. Neoadjuvant treatment for advanced esophageal cancer: response assessment before surgery and how to predict response to chemoradiation before starting treatment. Chin J Cancer Res 2015;27:221-30. [PMID: 26157318 DOI: 10.3978/j.issn.1000-9604.2015.04.04] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
43 Eyck BM, Onstenk BD, Noordman BJ, Nieboer D, Spaander MCW, Valkema R, Lagarde SM, Wijnhoven BPL, van Lanschot JJB. Accuracy of Detecting Residual Disease After Neoadjuvant Chemoradiotherapy for Esophageal Cancer: A Systematic Review and Meta-analysis. Ann Surg 2020;271:245-56. [PMID: 31188203 DOI: 10.1097/SLA.0000000000003397] [Cited by in Crossref: 17] [Cited by in F6Publishing: 9] [Article Influence: 17.0] [Reference Citation Analysis]
44 Brabender J, Arbab D, Huan X, Vallböhmer D, Grimminger P, Ling F, Neiss S, Bollschweiler E, Schneider PM, Hölscher AH. Death-associated protein kinase (DAPK) promoter methylation and response to neoadjuvant radiochemotherapy in esophageal cancer. Ann Surg Oncol. 2009;16:1378-1383. [PMID: 19224282 DOI: 10.1245/s10434-009-0356-1] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
45 Salnikova LE, Kolobkov DS. Germline and somatic genetic predictors of pathological response in neoadjuvant settings of rectal and esophageal cancers: systematic review and meta-analysis. Pharmacogenomics J 2016;16:249-65. [PMID: 26122021 DOI: 10.1038/tpj.2015.46] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
46 Klevebro F, Nilsson K, Lindblad M, Ekman S, Johansson J, Lundell L, Ndegwa N, Hedberg J, Nilsson M. Association between time interval from neoadjuvant chemoradiotherapy to surgery and complete histological tumor response in esophageal and gastroesophageal junction cancer: a national cohort study. Dis Esophagus. 2019;. [PMID: 31676895 DOI: 10.1093/dote/doz078] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
47 Koen Talsma A, Shapiro J, Looman CW, van Hagen P, Steyerberg EW, van der Gaast A, van Berge Henegouwen MI, Wijnhoven BP, van Lanschot JJ, Hulshof MC, van Laarhoven HW, Nieuwenhuijzen GA, Hospers GA, Bonenkamp JJ, Cuesta MA, Blaisse RJ, Busch OR, ten Kate FJ, Creemers GJ, Punt CJ, Plukker JT, Verheul HM, van Dekken H, van der Sangen MJ, Rozema T, Biermann K, Beukema JC, Piet AH, van Rij CM, Reinders JG, Tilanus HW; CROSS Study Group. Lymph node retrieval during esophagectomy with and without neoadjuvant chemoradiotherapy: prognostic and therapeutic impact on survival. Ann Surg 2014;260:786-92; discussion 792-3. [PMID: 25379850 DOI: 10.1097/SLA.0000000000000965] [Cited by in Crossref: 84] [Cited by in F6Publishing: 24] [Article Influence: 14.0] [Reference Citation Analysis]
48 Metzger R, Bollschweiler E, Hölscher AH, Warnecke-Eberz U. ERCC1: impact in multimodality treatment of upper gastrointestinal cancer. Future Oncol 2010;6:1735-49. [PMID: 21142660 DOI: 10.2217/fon.10.140] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
49 Donlon NE, Sheppard A, Davern M, O'Connell F, Phelan JJ, Power R, Nugent T, Dinneen K, Aird J, Greene J, Nevins Selvadurai P, Bhardwaj A, Foley EK, Ravi N, Donohoe CL, Reynolds JV, Lysaght J, O'Sullivan J, Dunne MR. Linking Circulating Serum Proteins with Clinical Outcomes in Esophageal Adenocarcinoma-An Emerging Role for Chemokines. Cancers (Basel) 2020;12:E3356. [PMID: 33202734 DOI: 10.3390/cancers12113356] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
50 Maurer J, Schöpp M, Thurau K, Haier J, Köhler G, Hummel R. Immunohistochemical analysis on potential new molecular targets for esophageal cancer. Dis Esophagus 2014;27:93-100. [PMID: 23551625 DOI: 10.1111/dote.12065] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
51 Hoeppner J, Zirlik K, Brunner T, Bronsert P, Kulemann B, Sick O, Marjanovic G, Hopt UT, Makowiec F. Multimodal treatment of locally advanced esophageal adenocarcinoma: Which regimen should we choose? Outcome analysis of perioperative chemotherapy versus neoadjuvant chemoradiation in 105 patients: Multimodal Therapy of Esophageal Adenocarcinoma. J Surg Oncol 2014;109:287-93. [DOI: 10.1002/jso.23498] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
52 Miyata H, Yamasaki M, Takahashi T, Murakami K, Tanaka K, Yukinori K, Nakajima K, Takiguchi S, Morii E, Hatazawa J, Mori M, Doki Y. Determinants of response to neoadjuvant chemotherapy for esophageal cancer using 18F-fluorodeoxiglucose positron emission tomography (18F-FDG-PET). Ann Surg Oncol 2014;21:575-82. [PMID: 24201746 DOI: 10.1245/s10434-013-3343-5] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
53 Zingg U, Montani M, Busch M, Metzger U, Went P, Oertli D. Prognostic influence of immunohistochemically detected lymph node micrometastasis and histological subtype in pN0 oesophageal cancer. European Journal of Surgical Oncology (EJSO) 2009;35:593-9. [DOI: 10.1016/j.ejso.2008.12.001] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
54 Huang Y, Wang H, Luo G, Zhang Y, Wang L, Li K. A systematic review and network meta-analysis of neoadjuvant therapy combined with surgery for patients with resectable esophageal squamous cell carcinoma. Int J Surg 2017;38:41-7. [PMID: 28027995 DOI: 10.1016/j.ijsu.2016.12.035] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
55 Lindner K, Fritz M, Haane C, Senninger N, Palmes D, Hummel R. Postoperative complications do not affect long-term outcome in esophageal cancer patients. World J Surg 2014;38:2652-61. [PMID: 24867467 DOI: 10.1007/s00268-014-2590-3] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 4.3] [Reference Citation Analysis]
56 Blank S, Knebel P, Haag GM, Bruckner T, Klaiber U, Burian M, Schaible A, Sisic L, Schmidt T, Diener MK, Ott K. Immediate tumor resection in patients with locally advanced gastroesophageal adenocarcinoma with nonresponse to chemotherapy after 4 weeks of treatment versus resection after completion of chemotherapy (OPTITREAT trial, DRKS00004668): study protocol for a randomized controlled pilot trial. Pilot Feasibility Stud 2016;2:18. [PMID: 27965838 DOI: 10.1186/s40814-016-0059-x] [Reference Citation Analysis]
57 Grillo F, Mastracci L, Saragoni L, Vanoli A, Limarzi F, Gullo I, Ferro J, Paudice M, Parente P, Fassan M. Neoplastic and pre-neoplastic lesions of the oesophagus and gastro-oesophageal junction. Pathologica 2020;112:138-52. [PMID: 33179618 DOI: 10.32074/1591-951X-164] [Reference Citation Analysis]
58 Bollschweiler E, Hölscher AH. Prognostic relevance of tumor response after neoadjuvant therapy for patients with esophageal cancer. Ann Transl Med 2019;7:S228. [PMID: 31656807 DOI: 10.21037/atm.2019.08.36] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
59 Rizk NP, Venkatraman E, Bains MS, Park B, Flores R, Tang L, Ilson DH, Minsky BD, Rusch VW. American Joint Committee on Cancer staging system does not accurately predict survival in patients receiving multimodality therapy for esophageal adenocarcinoma. J Clin Oncol. 2007;25:507-512. [PMID: 17290058 DOI: 10.1200/jco.2006.08.0101] [Cited by in Crossref: 135] [Cited by in F6Publishing: 46] [Article Influence: 9.6] [Reference Citation Analysis]
60 Favi F, Bollschweiler E, Berlth F, Plum P, Hescheler DA, Alakus H, Semrau R, Celik E, Mönig SP, Drebber U, Hölscher AH. Neoadjuvant chemotherapy or chemoradiation for patients with advanced adenocarcinoma of the oesophagus? A propensity score-matched study. Eur J Surg Oncol 2017;43:1572-80. [PMID: 28666624 DOI: 10.1016/j.ejso.2017.06.003] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
61 Prenzel KL, König A, Schneider PM, Schnickmann C, Baldus SE, Schröder W, Bollschweiler E, Dienes HP, Mueller RP, Izbicki JR, Hölscher AH. Reduced Incidence of Nodal Micrometastasis after Major Response to Neoadjuvant Chemoradiation in Locally Advanced Esophageal Cancer. Ann Surg Oncol 2007;14:954-9. [DOI: 10.1245/s10434-006-9141-6] [Cited by in Crossref: 32] [Cited by in F6Publishing: 24] [Article Influence: 2.1] [Reference Citation Analysis]
62 Chen SY, Molena D, Stem M, Mungo B, Lidor AO. Post-discharge complications after esophagectomy account for high readmission rates. World J Gastroenterol 2016;22:5246-53. [PMID: 27298567 DOI: 10.3748/wjg.v22.i22.5246] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
63 Noble F, Lloyd MA, Turkington R, Griffiths E, O'Donovan M, O'Neill JR, Mercer S, Parsons SL, Fitzgerald RC, Underwood TJ; OCCAMS consortium. Multicentre cohort study to define and validate pathological assessment of response to neoadjuvant therapy in oesophagogastric adenocarcinoma. Br J Surg 2017;104:1816-28. [PMID: 28944954 DOI: 10.1002/bjs.10627] [Cited by in Crossref: 42] [Cited by in F6Publishing: 37] [Article Influence: 10.5] [Reference Citation Analysis]
64 Siddiqui MR, Gormly KL, Bhoday J, Balyansikova S, Battersby NJ, Chand M, Rao S, Tekkis P, Abulafi AM, Brown G. Interobserver agreement of radiologists assessing the response of rectal cancers to preoperative chemoradiation using the MRI tumour regression grading (mrTRG). Clin Radiol 2016;71:854-62. [PMID: 27381221 DOI: 10.1016/j.crad.2016.05.005] [Cited by in Crossref: 30] [Cited by in F6Publishing: 22] [Article Influence: 6.0] [Reference Citation Analysis]
65 Matuschek C, Bölke E, Peiper M, Knoefel WT, Budach W, Erhardt A, Scherer A, Gerber PA, Buhren BA, Gattermann N, Baldus SE, Rusnak E, Shukla V, Orth K. The role of neoadjuvant and adjuvant treatment for adenocarcinoma of the upper gastrointestinal tract. Eur J Med Res 2011;16:265-74. [PMID: 21810561 DOI: 10.1186/2047-783x-16-6-265] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
66 Konieczny A, Meyer P, Schnider A, Komminoth P, Schmid M, Lombriser N, Weishaupt D. Accuracy of multidetector-row CT for restaging after neoadjuvant treatment in patients with oesophageal cancer. Eur Radiol. 2013;23:2492-2502. [PMID: 23645329 DOI: 10.1007/s00330-013-2844-8] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
67 Brabender J, Metzger R, Vallböhmer D, Ling F, Neiss S, Bollschweiler E, Schneider PM, Hölscher AH, Grimminger PP. Roles of thymidylate synthase and dihydropyrimidine dehydrogenase expression in blood as predictors of response to multimodal therapy in esophageal cancer. Surgery. 2012;151:306-312. [PMID: 21982526 DOI: 10.1016/j.surg.2011.07.018] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
68 Semrau R, Vallböhmer D, Hölscher AH, Müller RP. [Neoadjuvant therapy of adenocarcinomas of the upper gastrointestinal tract. Status of radiotherapy]. Chirurg 2009;80:1035-41. [PMID: 19820906 DOI: 10.1007/s00104-009-1737-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
69 Wang D, Smit JK, Zwaan E, Muijs CT, Groen H, Hollema H, Plukker JT. Neoadjuvant therapy reduces the incidence of nodal micrometastases in esophageal adenocarcinoma. The American Journal of Surgery 2013;206:732-8. [DOI: 10.1016/j.amjsurg.2013.03.004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
70 Vallböhmer D, Bollschweiler E, Brabender J, Wedemeyer I, Grimminger PP, Metzger R, Schröder W, Gutschow C, Hölscher AH, Drebber U. Evaluation of histological regression grading systems in the neoadjuvant therapy of rectal cancer: do they have prognostic impact? Int J Colorectal Dis. 2012;27:1295-1301. [PMID: 22614681 DOI: 10.1007/s00384-012-1487-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
71 Slotta-Huspenina J, Berg D, Bauer K, Wolff C, Malinowsky K, Bauer L, Drecoll E, Bettstetter M, Feith M, Walch A, Höfler H, Becker KF, Langer R. Evidence of prognostic relevant expression profiles of heat-shock proteins and glucose-regulated proteins in oesophageal adenocarcinomas. PLoS One 2012;7:e41420. [PMID: 22911792 DOI: 10.1371/journal.pone.0041420] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
72 Hindié E, Hennequin C, Moretti J. Predicting response to chemoradiotherapy in rectal and oesophageal cancer with 18F-FDG: prognostic value and possible role in patient management. Eur J Nucl Med Mol Imaging 2007;34:1576-82. [DOI: 10.1007/s00259-007-0483-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
73 Miyata H, Yamasaki M, Takahashi T, Murakami K, Kurokawa Y, Nakajima K, Takiguchi S, Mori M, Doki Y. Relevance of [18F]fluorodeoxyglucose positron emission tomography-positive lymph nodes after neoadjuvant chemotherapy for squamous cell oesophageal cancer. British Journal of Surgery 2013;100:1490-7. [DOI: 10.1002/bjs.9253] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
74 Karoui M, Koubaa W, Delbaldo C, Charachon A, Laurent A, Piedbois P, Cherqui D, Tran Van Nhieu J. Chemotherapy has also an effect on primary tumor in colon carcinoma. Ann Surg Oncol 2008;15:3440-6. [PMID: 18850249 DOI: 10.1245/s10434-008-0167-9] [Cited by in Crossref: 37] [Cited by in F6Publishing: 24] [Article Influence: 2.8] [Reference Citation Analysis]
75 Ooki A, Yamashita K, Kobayashi N, Katada N, Sakuramoto S, Kikuchi S, Watanabe M. Lymph node metastasis density and growth pattern as independent prognostic factors in advanced esophageal squamous cell carcinoma. World J Surg 2007;31:2184-91. [PMID: 17721721 DOI: 10.1007/s00268-007-9198-9] [Cited by in Crossref: 48] [Cited by in F6Publishing: 39] [Article Influence: 3.4] [Reference Citation Analysis]
76 Zahoor H, Luketich JD, Levy RM, Awais O, Winger DG, Gibson MK, Nason KS. A propensity-matched analysis comparing survival after primary minimally invasive esophagectomy followed by adjuvant therapy to neoadjuvant therapy for esophagogastric adenocarcinoma. J Thorac Cardiovasc Surg 2015;149:538-47. [PMID: 25454907 DOI: 10.1016/j.jtcvs.2014.10.044] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]
77 Lv J, Cao XF, Zhu B, Ji L, Tao L, Wang DD. Effect of neoadjuvant chemoradiotherapy on prognosis and surgery for esophageal carcinoma. World J Gastroenterol. 2009;15:4962-4968. [PMID: 19842230 DOI: 10.3748/wjg.15.4962] [Cited by in CrossRef: 50] [Cited by in F6Publishing: 48] [Article Influence: 4.5] [Reference Citation Analysis]
78 Maru DM, Luthra R, Correa AM, White-Cross J, Anandasabapathy S, Krishnan S, Guha S, Komaki R, Swisher SG, Ajani JA, Hofstetter WL, Rashid A. Frequent loss of heterozygosity of chromosome 1q in esophageal adenocarcinoma: loss of chromosome 1q21.3 is associated with shorter overall survival. Cancer 2009;115:1576-85. [PMID: 19156915 DOI: 10.1002/cncr.24122] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
79 Schneider PM, Metzger R, Schaefer H, Baumgarten F, Vallbohmer D, Brabender J, Wolfgarten E, Bollschweiler E, Baldus SE, Dienes HP, Hoelscher AH. Response Evaluation by Endoscopy, Rebiopsy, and Endoscopic Ultrasound Does Not Accurately Predict Histopathologic Regression After Neoadjuvant Chemoradiation for Esophageal Cancer. Annals of Surgery 2008;248:902-8. [DOI: 10.1097/sla.0b013e31818f3afb] [Cited by in Crossref: 117] [Cited by in F6Publishing: 31] [Article Influence: 9.0] [Reference Citation Analysis]
80 Jácome AA, Oliveira FA, Lino F, Lima JPSN. Effect of Adding Bevacizumab to Chemotherapy on Pathologic Response to Preoperative Systemic Therapy for Resectable Colorectal Liver Metastases: A Systematic Review and Meta-analysis. Clin Colorectal Cancer 2021;20:265-72. [PMID: 34158251 DOI: 10.1016/j.clcc.2021.05.006] [Reference Citation Analysis]
81 Puetz K, Bollschweiler E, Semrau R, Mönig SP, Hölscher AH, Drebber U. Neoadjuvant chemoradiation for patients with advanced oesophageal cancer - which response grading system best impacts prognostic discrimination? Histopathology 2019;74:731-43. [PMID: 30636069 DOI: 10.1111/his.13811] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
82 Warnecke-Eberz U, Vallböhmer D, Alakus H, Kütting F, Lurje G, Bollschweiler E, Wienand-Dorweiler A, Drebber U, Hölscher AH, Metzger R. ERCC1 and XRCC1 gene polymorphisms predict response to neoadjuvant radiochemotherapy in esophageal cancer. J Gastrointest Surg. 2009;13:1411-1421. [PMID: 19421825 DOI: 10.1007/s11605-009-0881-z] [Cited by in Crossref: 44] [Cited by in F6Publishing: 39] [Article Influence: 3.7] [Reference Citation Analysis]
83 Jiao R, Zheng X, Sun Y, Feng Z, Song S, Ge H. IDO1 Expression Increased After Neoadjuvant Therapy Predicts Poor Pathologic Response and Prognosis in Esophageal Squamous Cell Carcinoma. Front Oncol 2020;10:1099. [PMID: 32733806 DOI: 10.3389/fonc.2020.01099] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
84 Karoui M, Rullier A, Luciani A, Bonnetain F, Auriault ML, Sarran A, Monges G, Trillaud H, Le Malicot K, Leroy K, Sobhani I, Bardier A, Moreau M, Brindel I, Seitz JF, Taieb J. Neoadjuvant FOLFOX 4 versus FOLFOX 4 with Cetuximab versus immediate surgery for high-risk stage II and III colon cancers: a multicentre randomised controlled phase II trial--the PRODIGE 22--ECKINOXE trial. BMC Cancer 2015;15:511. [PMID: 26156156 DOI: 10.1186/s12885-015-1507-3] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 4.2] [Reference Citation Analysis]
85 Bollschweiler E, Baldus SE, Schröder W, Schneider PM, Hölscher AH. Staging of esophageal carcinoma: length of tumor and number of involved regional lymph nodes. Are these independent prognostic factors? J Surg Oncol. 2006;94:355-363. [PMID: 16967455 DOI: 10.1002/jso.20569] [Cited by in Crossref: 110] [Cited by in F6Publishing: 100] [Article Influence: 7.3] [Reference Citation Analysis]
86 Grimminger P, Vallböhmer D, Hoffmann A, Schulte C, Bollschweiler E, Schneider PM, Hölscher AH, Metzger R, Brabender J. Quantitative analysis of survivin RNA expression in blood as a non-invasive predictor of response to neoadjuvant radiochemotherapy in esophageal cancer. J Surg Oncol. 2009;100:447-451. [PMID: 19653263 DOI: 10.1002/jso.21355] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
87 Barbour AP, Jones M, Gonen M, Gotley DC, Thomas J, Thomson DB, Burmeister B, Smithers BM. Refining esophageal cancer staging after neoadjuvant therapy: importance of treatment response. Ann Surg Oncol. 2008;15:2894-2902. [PMID: 18663531 DOI: 10.1245/s10434-008-0084-y] [Cited by in Crossref: 55] [Cited by in F6Publishing: 40] [Article Influence: 4.2] [Reference Citation Analysis]
88 Nieman DR, Peyre CG, Watson TJ, Cao W, Lunt MD, Lada MJ, Han MS, Jones CE, Peters JH. Neoadjuvant treatment response in negative nodes is an important prognosticator after esophagectomy. Ann Thorac Surg 2015;99:277-83. [PMID: 25442991 DOI: 10.1016/j.athoracsur.2014.07.037] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 3.4] [Reference Citation Analysis]
89 Ling FC, Vallböhmer D, Hoelscher AH, Schmidt D, Bollschweiler E, Schneider PM. Increased platelet counts after transthoracic en bloc resection for esophageal cancer is associated with significantly improved survival. World J Surg 2010;34:2628-34. [PMID: 20652700 DOI: 10.1007/s00268-010-0707-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
90 Kim JY, Hofstetter WL. Esophagectomy after chemoradiation: who and when to operate. Semin Thorac Cardiovasc Surg 2012;24:288-93. [PMID: 23465677 DOI: 10.1053/j.semtcvs.2012.10.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
91 Blackham AU, Yue B, Almhanna K, Saeed N, Fontaine JP, Hoffe S, Shridhar R, Frakes J, Coppola D, Pimiento JM. The prognostic value of residual nodal disease following neoadjuvant chemoradiation for esophageal cancer in patients with complete primary tumor response: ypT0N+ Esophageal Cancer. J Surg Oncol 2015;112:597-602. [DOI: 10.1002/jso.24050] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 3.5] [Reference Citation Analysis]
92 Chen SB, Weng HR, Wang G, Yang JS, Yang WP, Liu DT, Chen YP, Zhang H. Prognostic factors and outcome for patients with esophageal squamous cell carcinoma underwent surgical resection alone: evaluation of the seventh edition of the American Joint Committee on Cancer staging system for esophageal squamous cell carcinoma. J Thorac Oncol. 2013;8:495-501. [PMID: 23446203 DOI: 10.1097/jto.0b013e3182829e2c] [Cited by in Crossref: 40] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
93 Chao YK, Chang CB, Chuang WY, Wen YW, Chang HK, Tseng CK, Yeh CJ, Liu YH. Correlation Between Tumor Regression Grade and Clinicopathological Parameters in Patients With Squamous Cell Carcinoma of the Esophagus Who Received Neoadjuvant Chemoradiotherapy. Medicine (Baltimore). 2015;94:e1407. [PMID: 26313788 DOI: 10.1097/MD.0000000000001407] [Cited by in Crossref: 11] [Cited by in F6Publishing: 2] [Article Influence: 1.8] [Reference Citation Analysis]
94 Noble F, Nolan L, Bateman AC, Byrne JP, Kelly JJ, Bailey IS, Sharland DM, Rees CN, Iveson TJ, Underwood TJ, Bateman AR. Refining pathological evaluation of neoadjuvant therapy for adenocarcinoma of the esophagus. World J Gastroenterol 2013;19:9282-93. [PMID: 24409055 DOI: 10.3748/wjg.v19.i48.9282] [Cited by in CrossRef: 34] [Cited by in F6Publishing: 28] [Article Influence: 4.9] [Reference Citation Analysis]
95 Kim HJ, Jo JS, Lee SY, Kim CH, Kim YJ, Kim HR. Low Lymph Node Retrieval After Preoperative Chemoradiation for Rectal Cancer is Associated with Improved Prognosis in Patients with a Good Tumor Response. Ann Surg Oncol. 2015;22:2075-2081. [PMID: 25395150 DOI: 10.1245/s10434-014-4235-z] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 3.6] [Reference Citation Analysis]
96 Shapiro J, van Klaveren D, Lagarde SM, Toxopeus ELA, van der Gaast A, Hulshof MCCM, Wijnhoven BPL, van Berge Henegouwen MI, Steyerberg EW, van Lanschot JJB. Prediction of survival in patients with oesophageal or junctional cancer receiving neoadjuvant chemoradiotherapy and surgery. British Journal of Surgery 2016;103:1039-47. [DOI: 10.1002/bjs.10142] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
97 Metzger R, Bollschweiler E, Drebber U, Mönig SP, Schröder W, Alakus H, Kocher M, Baldus SE, Hölscher AH. Neoadjuvant chemoradiotherapy for esophageal cancer: impact on extracapsular lymph node involvement. World J Gastroenterol 2010;16:1986-92. [PMID: 20419835 DOI: 10.3748/wjg.v16.i16.1986] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
98 Tong Y, Liu D, Zhang J. Connection and distinction of tumor regression grading systems of gastrointestinal cancer. Pathol Res Pract 2020;216:153073. [PMID: 32825946 DOI: 10.1016/j.prp.2020.153073] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
99 Verlato G, Zanoni A, Tomezzoli A, Minicozzi A, Giacopuzzi S, Di Cosmo M, Franceschetti I, de Manzoni G. Response to induction therapy in oesophageal and cardia carcinoma using Mandard tumour regression grade or size of residual foci. Br J Surg. 2010;97:719-725. [PMID: 20306529 DOI: 10.1002/bjs.6949] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
100 Westerhoff M, Osecky M, Langer R. Varying practices in tumor regression grading of gastrointestinal carcinomas after neoadjuvant therapy: results of an international survey. Mod Pathol 2020;33:676-89. [PMID: 31673084 DOI: 10.1038/s41379-019-0393-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
101 Schneider PM, Eshmuminov D, Rordorf T, Vetter D, Veit-Haibach P, Weber A, Bauerfeind P, Samaras P, Lehmann K. 18FDG-PET-CT identifies histopathological non-responders after neoadjuvant chemotherapy in locally advanced gastric and cardia cancer: cohort study. BMC Cancer 2018;18:548. [PMID: 29743108 DOI: 10.1186/s12885-018-4477-4] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
102 Bollschweiler E, Hölscher AH, Metzger R, Besch S, Mönig SP, Baldus SE, Drebber U. Prognostic significance of a new grading system of lymph node morphology after neoadjuvant radiochemotherapy for esophageal cancer. Ann Thorac Surg. 2011;92:2020-2027. [PMID: 22115212 DOI: 10.1016/j.athoracsur.2011.06.091] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 3.1] [Reference Citation Analysis]
103 Miyata H, Yamasaki M, Kurokawa Y, Takiguchi S, Nakajima K, Fujiwara Y, Mori M, Doki Y. Clinical relevance of induction triplet chemotherapy for esophageal cancer invading adjacent organs. J Surg Oncol 2012;106:441-7. [PMID: 22371189 DOI: 10.1002/jso.23081] [Cited by in Crossref: 30] [Cited by in F6Publishing: 21] [Article Influence: 3.3] [Reference Citation Analysis]
104 Depypere L, De Hertogh G, Moons J, Provoost AL, Lerut T, Sagaert X, Coosemans W, Van Veer H, Nafteux P. Importance of Lymph Node Response After Neoadjuvant Chemoradiotherapy for Esophageal Adenocarcinoma. Ann Thorac Surg 2020:S0003-4975(20)32144-5. [PMID: 33352178 DOI: 10.1016/j.athoracsur.2020.09.074] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
105 Metzger R, Warnecke-Eberz U, Alakus H, Kütting F, Brabender J, Vallböhmer D, Grimminger PP, Mönig SP, Drebber U, Hölscher AH. Neoadjuvant radiochemotherapy in adenocarcinoma of the esophagus: ERCC1 gene polymorphisms for prediction of response and prognosis. J Gastrointest Surg. 2012;16:26-34; discussion 34. [PMID: 21956434 DOI: 10.1007/s11605-011-1700-x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 3.2] [Reference Citation Analysis]
106 Bollschweiler E, Hölscher AH, Metzger R. Histologic tumor type and the rate of complete response after neoadjuvant therapy for esophageal cancer. Future Oncology 2010;6:25-35. [DOI: 10.2217/fon.09.133] [Cited by in Crossref: 38] [Cited by in F6Publishing: 33] [Article Influence: 3.5] [Reference Citation Analysis]
107 Prenzel KL, Hölscher AH, Drebber U, Agavonova M, Gutschow CA, Bollschweiler E. Prognostic impact of nodal micrometastasis in early esophageal cancer. Eur J Surg Oncol. 2012;38:314-318. [PMID: 22277724 DOI: 10.1016/j.ejso.2012.01.007] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 3.4] [Reference Citation Analysis]
108 Lee JM, Yang PW, Yang SY, Chuang TH, Tung EC, Chen JS, Huang PM, Lee YC. Genetic variants in DNA repair predicts the survival of patients with esophageal cancer. Ann Surg 2011;253:918-27. [PMID: 21490450 DOI: 10.1097/SLA.0b013e318216f374] [Cited by in Crossref: 18] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
109 Rizk NP, Seshan VE, Bains MS, Ilson DH, Minsky BD, Tang L, Rusch VW. Prognostic factors after combined modality treatment of squamous cell carcinoma of the esophagus. J Thorac Oncol. 2007;2:1117-1123. [PMID: 18090585 DOI: 10.1097/JTO.0b013e31815bfe53] [Cited by in Crossref: 27] [Cited by in F6Publishing: 7] [Article Influence: 2.1] [Reference Citation Analysis]
110 Hölscher AH, Vallböhmer D, Brabender J. The prevention and management of perioperative complications. Best Pract Res Clin Gastroenterol. 2006;20:907-923. [PMID: 16997169 DOI: 10.1016/j.bpg.2006.05.002] [Cited by in Crossref: 33] [Cited by in F6Publishing: 23] [Article Influence: 2.4] [Reference Citation Analysis]
111 Lurje G, Lenz HJ. Molecular response prediction in multimodality treatment for adenocarcinoma of the esophagus and esophagogastric junction. Recent Results Cancer Res 2010;182:179-91. [PMID: 20676881 DOI: 10.1007/978-3-540-70579-6_15] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
112 Tiesi G, Park W, Gunder M, Rubio G, Berger M, Ardalan B, Livingstone A, Franceschi D. Long-term survival based on pathologic response to neoadjuvant therapy in esophageal cancer. J Surg Res 2017;216:65-72. [PMID: 28807215 DOI: 10.1016/j.jss.2017.03.022] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
113 Langer R, Ott K, Feith M, Lordick F, Siewert JR, Becker K. Prognostic significance of histopathological tumor regression after neoadjuvant chemotherapy in esophageal adenocarcinomas. Mod Pathol. 2009;22:1555-1563. [PMID: 19801967 DOI: 10.1038/modpathol.2009.123] [Cited by in Crossref: 70] [Cited by in F6Publishing: 63] [Article Influence: 5.8] [Reference Citation Analysis]
114 Davarzani N, Hutchins GGA, West NP, Hewitt LC, Nankivell M, Cunningham D, Allum WH, Smyth E, Valeri N, Langley RE, Grabsch HI. Prognostic value of pathological lymph node status and primary tumour regression grading following neoadjuvant chemotherapy - results from the MRC OE02 oesophageal cancer trial. Histopathology 2018;72:1180-8. [PMID: 29465751 DOI: 10.1111/his.13491] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
115 Vallböhmer D, Kuhn E, Warnecke-eberz U, Brabender J, Hoffmann AC, Metzger R, Baldus SE, Drebber U, Hoelscher AH, Schneider PM. Failure in downregulation of intratumoral survivin expression following neoadjuvant chemoradiation in esophageal cancer. Pharmacogenomics 2008;9:681-90. [DOI: 10.2217/14622416.9.6.681] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
116 Trowbridge R, Sharma P, Hunter WJ, Agrawal DK. Vitamin D receptor expression and neoadjuvant therapy in esophageal adenocarcinoma. Exp Mol Pathol. 2012;93:147-153. [PMID: 22546272 DOI: 10.1016/j.yexmp.2012.04.018] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
117 Shapiro J, Biermann K, van Klaveren D, Offerhaus GJ, Ten Kate FJ, Meijer SL, van Berge Henegouwen MI, Steyerberg EW, Wijnhoven BP, Lanschot JJ. Prognostic Value of Pretreatment Pathological Tumor Extent in Patients Treated With Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal or Junctional Cancer. Ann Surg 2017;265:356-62. [PMID: 28059964 DOI: 10.1097/SLA.0000000000001630] [Cited by in Crossref: 24] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
118 Ge H, Lu Y, Chen Y, Zheng X, Wang W, Yu J. ERCC1 expression and tumor regression predict survival in esophageal squamous cell carcinoma patients receiving combined trimodality therapy. Pathol Res Pract. 2014;210:656-661. [PMID: 25042384 DOI: 10.1016/j.prp.2014.06.013] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
119 Tong DK, Law S, Kwong DL, Chan KW, Lam AK, Wong KH. Histological regression of squamous esophageal carcinoma assessed by percentage of residual viable cells after neoadjuvant chemoradiation is an important prognostic factor. Ann Surg Oncol 2010;17:2184-92. [PMID: 20217248 DOI: 10.1245/s10434-010-0995-2] [Cited by in Crossref: 53] [Cited by in F6Publishing: 43] [Article Influence: 4.8] [Reference Citation Analysis]
120 Rice TW, Ishwaran H, Kelsen DP, Hofstetter WL, Apperson-Hansen C, Blackstone EH; Worldwide Esophageal Cancer Collaboration Investigators. Recommendations for neoadjuvant pathologic staging (ypTNM) of cancer of the esophagus and esophagogastric junction for the 8th edition AJCC/UICC staging manuals. Dis Esophagus. 2016;29:906-912. [PMID: 27905170 DOI: 10.1111/dote.12538] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 8.5] [Reference Citation Analysis]
121 Hölscher AH, Bollschweiler E, Schröder W, Metzger R, Gutschow C, Drebber U. Prognostic impact of upper, middle, and lower third mucosal or submucosal infiltration in early esophageal cancer. Ann Surg. 2011;254:802-807; discussion 807-808. [PMID: 22042472 DOI: 10.1097/sla.0b013e3182369128] [Cited by in Crossref: 84] [Cited by in F6Publishing: 24] [Article Influence: 9.3] [Reference Citation Analysis]
122 Kim MK, Cho K, Park S, Kim YH, Kim JH, Song H, Shin JH, Jung HY, Lee GH, Choi KD, Song HJ, Ryu J, Kim S. Initial Stage Affects Survival Even After Complete Pathologic Remission is Achieved in Locally Advanced Esophageal Cancer: Analysis of 70 Patients With Pathologic Major Response After Preoperative Chemoradiotherapy. International Journal of Radiation Oncology*Biology*Physics 2009;75:115-21. [DOI: 10.1016/j.ijrobp.2008.10.074] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
123 Hagens E, Tukanova K, Jamel S, van Berge Henegouwen M, Hanna GB, Gisbertz S, Markar SR. Prognostic relevance of lymph node regression on survival in esophageal cancer: a systematic review and meta-analysis. Dis Esophagus 2021:doab021. [PMID: 33893494 DOI: 10.1093/dote/doab021] [Reference Citation Analysis]
124 Tao CJ, Lin G, Xu YP, Mao WM. Predicting the Response of Neoadjuvant Therapy for Patients with Esophageal Carcinoma: an In-depth Literature Review. J Cancer 2015;6:1179-86. [PMID: 26516367 DOI: 10.7150/jca.12346] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
125 Yuan Y, Ma G, Hu X, Huang Q. Evaluating the eighth edition TNM staging system for esophageal cancer among patients receiving neoadjuvant therapy: A SEER study. Cancer Med 2020;9:4648-55. [PMID: 32391623 DOI: 10.1002/cam4.2997] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
126 O'Sullivan KE, Hurley ET, Hurley JP. Understanding Complete Pathologic Response in Oesophageal Cancer: Implications for Management and Survival. Gastroenterol Res Pract 2015;2015:518281. [PMID: 26246803 DOI: 10.1155/2015/518281] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
127 Saliba G, Detlefsen S, Carneiro F, Conner J, Dorer R, Fléjou JF, Hahn H, Kamaradova K, Mastracci L, Meijer SL, Sabo E, Sheahan K, Riddell R, Wang N, Yantiss RK, Lundell L, Low D, Vieth M, Klevebro F. Tumor regression grading after neoadjuvant treatment of esophageal and gastroesophageal junction adenocarcinoma: results of an international Delphi consensus survey. Hum Pathol 2021;108:60-7. [PMID: 33221343 DOI: 10.1016/j.humpath.2020.11.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
128 Vallböhmer D, Hölscher AH, Dietlein M, Bollschweiler E, Baldus SE, Mönig SP, Metzger R, Schicha H, Schmidt M. [18F]-Fluorodeoxyglucose-positron emission tomography for the assessment of histopathologic response and prognosis after completion of neoadjuvant chemoradiation in esophageal cancer. Ann Surg. 2009;250:888-894. [PMID: 19953708 DOI: 10.1097/sla.0b013e3181bc9c0d] [Cited by in Crossref: 87] [Cited by in F6Publishing: 23] [Article Influence: 7.9] [Reference Citation Analysis]
129 Tirumani H, Rosenthal MH, Tirumani SH, Shinagare AB, Krajewski KM, Ramaiya NH. Esophageal Carcinoma: Current Concepts in the Role of Imaging in Staging and Management. Can Assoc Radiol J 2015;66:130-9. [DOI: 10.1016/j.carj.2014.08.006] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 3.5] [Reference Citation Analysis]
130 Alakus H, Bollschweiler E, Hölscher AH, Warnecke-Eberz U, Frazer KA, Harismendy O, Lowy AM, Mönig SP, Eberz PM, Maus M, Drebber U, Siffert W, Metzger R. Homozygous GNAS 393C-allele carriers with locally advanced esophageal cancer fail to benefit from platinum-based preoperative chemoradiotherapy. Ann Surg Oncol 2014;21:4375-82. [PMID: 24986238 DOI: 10.1245/s10434-014-3843-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
131 Chen JX, Lu TY, Fang HY, Lin YS, Lee JM. The Impact of Pretreatment PET/CT Nodal Status on Esophageal Squamous Cell Carcinoma After Neoadjuvant Chemoradiation. World J Surg 2020;44:2323-31. [PMID: 32296872 DOI: 10.1007/s00268-020-05481-7] [Reference Citation Analysis]
132 Hölscher AH, Schneider PM, Gutschow C, Schröder W. Laparoscopic ischemic conditioning of the stomach for esophageal replacement. Ann Surg 2007;245:241-6. [PMID: 17245177 DOI: 10.1097/01.sla.0000245847.40779.10] [Cited by in Crossref: 157] [Cited by in F6Publishing: 118] [Article Influence: 11.2] [Reference Citation Analysis]
133 Singh S, Bisht N, Sarin A, Kumar AVSA, Gupta S, Kapoor A, Mishra PS. Using positron-emission tomography-computed tomography for predicting radiotherapy-induced tumor regression in carcinoma esophagus in an Indian population. World J Nucl Med 2019;18:361-5. [PMID: 31933551 DOI: 10.4103/wjnm.WJNM_114_18] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
134 Sun F, Chen T, Han J, Ye P, Hu J. Staging accuracy of endoscopic ultrasound for esophageal cancer after neoadjuvant chemotherapy: a meta-analysis and systematic review: Staging accuracy of EUS. Dis Esophagus 2015;28:757-71. [DOI: 10.1111/dote.12274] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 2.7] [Reference Citation Analysis]
135 Sihag S, Nobel T, Hsu M, Torre S, Tan KS, Janjigian YY, Ku GY, Tang LH, Wu AJ, Maron SB, Bains MS, Jones DR, Molena D. Survival Following Trimodality Therapy in Patients With Locally Advanced Esophagogastric Adenocarcinoma: Does Only a Complete Pathologic Response Matter? Ann Surg 2020. [PMID: 33214465 DOI: 10.1097/SLA.0000000000004638] [Reference Citation Analysis]
136 Hoffmann AC, Vallböhmer D, Grimminger P, Metzger R, Prenzel KL, Hoelscher AH, Brabender J. Preoperative survivin mRNA detection in peripheral blood is an independent predictor of outcome in esophageal carcinoma. Pharmacogenomics. 2010;11:341-347. [PMID: 20235790 DOI: 10.2217/pgs.09.164] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.6] [Reference Citation Analysis]
137 Hummel R, Watson DI, Smith C, Kist J, Michael MZ, Haier J, Hussey DJ. Mir-148a improves response to chemotherapy in sensitive and resistant oesophageal adenocarcinoma and squamous cell carcinoma cells. J Gastrointest Surg. 2011;15:429-438. [PMID: 21246413 DOI: 10.1007/s11605-011-1418-9] [Cited by in Crossref: 66] [Cited by in F6Publishing: 63] [Article Influence: 6.6] [Reference Citation Analysis]
138 Zhao X, Ren Y, Hu Y, Cui N, Wang X, Cui Y. Neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the esophagus or the gastroesophageal junction: A meta-analysis based on clinical trials. PLoS One 2018;13:e0202185. [PMID: 30138325 DOI: 10.1371/journal.pone.0202185] [Cited by in Crossref: 22] [Cited by in F6Publishing: 15] [Article Influence: 7.3] [Reference Citation Analysis]
139 Vallböhmer D, Hölscher AH, Schneider PM, Schmidt M, Dietlein M, Bollschweiler E, Baldus S, Alakus H, Brabender J, Metzger R. [18F]-fluorodeoxyglucose-positron emission tomography for the assessment of histopathologic response and prognosis after completion of neoadjuvant chemotherapy in gastric cancer. J Surg Oncol. 2010;102:135-140. [PMID: 20648583 DOI: 10.1002/jso.21592] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 2.5] [Reference Citation Analysis]
140 Piessen G, Petyt G, Duhamel A, Mirabel X, Huglo D, Mariette C. Ineffectiveness of 18F-Fluorodeoxyglucose Positron Emission Tomography in the Evaluation of Tumor Response After Completion of Neoadjuvant Chemoradiation in Esophageal Cancer. Annals of Surgery 2013;258:66-76. [DOI: 10.1097/sla.0b013e31828676c4] [Cited by in Crossref: 51] [Cited by in F6Publishing: 7] [Article Influence: 6.4] [Reference Citation Analysis]
141 Smithers BM, Thomson I. Neoadjuvant Chemotherapy or Chemoradiotherapy for Locally Advanced Esophageal Cancer. Thoracic Surgery Clinics 2013;23:509-23. [DOI: 10.1016/j.thorsurg.2013.07.005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
142 Ferron J, Uzan C, Rey A, Gouy S, Pautier P, Lhommé C, Duvillard P, Morice P. Histological response is not a prognostic factor after neoadjuvant chemotherapy in advanced-stage ovarian cancer with no residual disease. European Journal of Obstetrics & Gynecology and Reproductive Biology 2009;147:101-5. [DOI: 10.1016/j.ejogrb.2009.07.016] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
143 Miyata H, Yamasaki M, Takiguchi S, Nakajima K, Fujiwara Y, Konishi K, Morii E, Mori M, Doki Y. Prognostic Value of Endoscopic Biopsy Findings After Induction Chemoradiotherapy With and Without Surgery for Esophageal Cancer. Annals of Surgery 2011;253:279-84. [DOI: 10.1097/sla.0b013e318206824f] [Cited by in Crossref: 36] [Cited by in F6Publishing: 4] [Article Influence: 3.6] [Reference Citation Analysis]
144 Aichler M, Motschmann M, Jütting U, Luber B, Becker K, Ott K, Lordick F, Langer R, Feith M, Siewert JR, Walch A. Epidermal growth factor receptor (EGFR) is an independent adverse prognostic factor in esophageal adenocarcinoma patients treated with cisplatin-based neoadjuvant chemotherapy. Oncotarget 2014;5:6620-32. [PMID: 25216514 DOI: 10.18632/oncotarget.2268] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 3.2] [Reference Citation Analysis]
145 Luc G, Gronnier C, Lebreton G, Brigand C, Mabrut JY, Bail JP, Meunier B, Collet D, Mariette C. Predictive Factors of Recurrence in Patients with Pathological Complete Response After Esophagectomy Following Neoadjuvant Chemoradiotherapy for Esophageal Cancer: A Multicenter Study. Ann Surg Oncol 2015;22 Suppl 3:S1357-64. [PMID: 26014152 DOI: 10.1245/s10434-015-4619-8] [Cited by in Crossref: 25] [Cited by in F6Publishing: 15] [Article Influence: 4.2] [Reference Citation Analysis]
146 Miyata H, Yamasaki M, Miyazaki Y, Takahashi T, Kurokawa Y, Nakajima K, Takiguchi S, Mori M, Doki Y. Clinical Importance of Supraclavicular Lymph Node Metastasis After Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma. Annals of Surgery 2015;262:280-5. [DOI: 10.1097/sla.0000000000000933] [Cited by in Crossref: 26] [Cited by in F6Publishing: 9] [Article Influence: 4.3] [Reference Citation Analysis]
147 Slotta-Huspenina J, Drecoll E, Feith M, Habermehl D, Combs S, Weichert W, Bettstetter M, Becker K, Langer R. MicroRNA expression profiling for the prediction of resistance to neoadjuvant radiochemotherapy in squamous cell carcinoma of the esophagus. J Transl Med. 2018;16:109. [PMID: 29695253 DOI: 10.1186/s12967-018-1492-9] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 5.7] [Reference Citation Analysis]
148 Philippron A, Bollschweiler E, Kunikata A, Plum P, Schmidt C, Favi F, Drebber U, Hölscher AH. Prognostic Relevance of Lymph Node Regression After Neoadjuvant Chemoradiation for Esophageal Cancer. Semin Thorac Cardiovasc Surg 2016;28:549-58. [PMID: 28043475 DOI: 10.1053/j.semtcvs.2016.04.003] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
149 Vallböhmer D, Drebber U, Schneider PM, Baldus S, Bollschweiler E, Brabender J, Warnecke-Eberz U, Mönig S, Hölscher AH, Metzger R. Survivin expression in gastric cancer: Association with histomorphological response to neoadjuvant therapy and prognosis. J Surg Oncol. 2009;99:409-413. [PMID: 19347901 DOI: 10.1002/jso.21271] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
150 Ott K, Blank S, Becker K, Langer R, Weichert W, Roth W, Sisic L, Stange A, Jäger D, Büchler M. Factors predicting prognosis and recurrence in patients with esophago-gastric adenocarcinoma and histopathological response with less than 10 % residual tumor. Langenbecks Arch Surg. 2013;398:239-249. [PMID: 23269519 DOI: 10.1007/s00423-012-1039-0] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
151 Guo K, Cai L, Zhang Y, Zhu JF, Rong TH, Lin P, Hao CL, Wang WP, Li Z, Zhang LJ. The predictive value of histological tumor regression grading (TRG) for therapeutic evaluation in locally advanced esophageal carcinoma treated with neoadjuvant chemotherapy. Chin J Cancer. 2012;31:399-408. [PMID: 22572013 DOI: 10.5732/cjc.011.10406] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
152 Eriksen AHM, Sørensen FB, Andersen RF, Jakobsen A, Hansen TF. Association between the expression of microRNAs and the response of patients with locally advanced rectal cancer to preoperative chemoradiotherapy. Oncol Lett 2017;14:201-9. [PMID: 28693154 DOI: 10.3892/ol.2017.6141] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
153 Vallböhmer D, Hölscher AH, Brabender J, Prenzel K, Gutschow C, Schröder W, Metzger R, Bollschweiler E. Clinicopathologic and prognostic factors of young and elderly patients with esophageal adenocarcinoma: is there really a difference? Dis Esophagus 2008;21:596-600. [PMID: 18430182 DOI: 10.1111/j.1442-2050.2008.00817.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
154 Gubler C, Schneider PM, Bauerfeind P. Complex anastomotic leaks following esophageal resections: the new stent over sponge (SOS) approach. Dis Esophagus. 2013;26:598-602. [PMID: 23199232 DOI: 10.1111/dote.12005] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
155 Schmidt M, Bollschweiler E, Dietlein M, Mönig SP, Kobe C, Vallboehmer D, Eschner W, Hölscher A, Schicha H. Mean and maximum standardized uptake values in [18F]FDG-PET for assessment of histopathological response in oesophageal squamous cell carcinoma or adenocarcinoma after radiochemotherapy. Eur J Nucl Med Mol Imaging 2009;36:735-44. [DOI: 10.1007/s00259-008-1011-y] [Cited by in Crossref: 36] [Cited by in F6Publishing: 28] [Article Influence: 2.8] [Reference Citation Analysis]
156 Bollschweiler E, Metzger R, Drebber U, Baldus S, Vallböhmer D, Kocher M, Hölscher AH. Histological type of esophageal cancer might affect response to neo-adjuvant radiochemotherapy and subsequent prognosis. Ann Oncol. 2009;20:231-238. [PMID: 18836090 DOI: 10.1093/annonc/mdn622] [Cited by in Crossref: 78] [Cited by in F6Publishing: 69] [Article Influence: 6.0] [Reference Citation Analysis]
157 Zhang X, Jain D. Updates in staging and pathologic evaluation of esophageal carcinoma following neoadjuvant therapy. Ann N Y Acad Sci 2020;1482:163-76. [PMID: 32892349 DOI: 10.1111/nyas.14462] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
158 Jiao W, Xu J, Zheng J, Shen Y, Lin L, Li J. Elevation of circulating big endothelin-1: an independent prognostic factor for tumor recurrence and survival in patients with esophageal squamous cell carcinoma. BMC Cancer 2008;8:334. [PMID: 19014602 DOI: 10.1186/1471-2407-8-334] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
159 Donohoe CL, O'farrell NJ, Grant T, King S, Clarke L, Muldoon C, Reynolds JV. Classification of Pathologic Response to Neoadjuvant Therapy in Esophageal and Junctional Cancer: Assessment of Existing Measures and Proposal of a Novel 3-Point Standard. Annals of Surgery 2013;258:784-92. [DOI: 10.1097/sla.0b013e3182a66588] [Cited by in Crossref: 52] [Cited by in F6Publishing: 19] [Article Influence: 6.5] [Reference Citation Analysis]
160 Miyata H, Yamasaki M, Makino T, Miyazaki Y, Takahashi T, Kurokawa Y, Nakajima K, Takiguchi S, Mori M, Doki Y. Therapeutic value of lymph node dissection for esophageal squamous cell carcinoma after neoadjuvant chemotherapy. J Surg Oncol 2015;112:60-5. [PMID: 26179950 DOI: 10.1002/jso.23965] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
161 Jost C, Binek J, Schuller JC, Bauerfeind P, Metzger U, Werth B, Knuchel J, Frossard J, Bertschinger P, Brauchli P, Meyenberger C, Ruhstaller T. Endosonographic radial tumor thickness after neoadjuvant chemoradiation therapy to predict response and survival in patients with locally advanced esophageal cancer: a prospective multicenter phase ll study by the Swiss Group for Clinical Cancer Research (SAKK 75/02). Gastrointestinal Endoscopy 2010;71:1114-21. [DOI: 10.1016/j.gie.2009.12.015] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 2.5] [Reference Citation Analysis]
162 Langer R, Becker K. Tumor regression grading of gastrointestinal cancers after neoadjuvant therapy. Virchows Arch 2018;472:175-86. [PMID: 28918544 DOI: 10.1007/s00428-017-2232-x] [Cited by in Crossref: 36] [Cited by in F6Publishing: 29] [Article Influence: 9.0] [Reference Citation Analysis]
163 Arnett ALH, Merrell KW, Macintosh EM, James SE, Nathan MA, Shen KR, Ravi K, Neben Wittich MA, Haddock MG, Hallemeier CL. Utility of 18F-FDG PET for Predicting Histopathologic Response in Esophageal Carcinoma following Chemoradiation. J Thorac Oncol 2017;12:121-8. [PMID: 27569732 DOI: 10.1016/j.jtho.2016.08.136] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 2.6] [Reference Citation Analysis]
164 Molena D, Sun HH, Badr AS, Mungo B, Sarkaria IS, Adusumilli PS, Bains MS, Rusch VW, Ilson DH, Rizk NP. Clinical tools do not predict pathological complete response in patients with esophageal squamous cell cancer treated with definitive chemoradiotherapy. Dis Esophagus 2014;27:355-9. [PMID: 24033404 DOI: 10.1111/dote.12126] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
165 Lerttanatum N, Tharavej C, Chongpison Y, Sanpavat A. Comparison of tumor regression grading system in locally advanced esophageal squamous cell carcinoma after preoperative radio-chemotherapy to determine the most accurate system predicting prognosis. J Gastrointest Oncol 2019;10:276-82. [PMID: 31032095 DOI: 10.21037/jgo.2018.12.01] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
166 Warnecke-Eberz U, Metzger R, Bollschweiler E, Baldus SE, Mueller RP, Dienes HP, Hoelscher AH, Schneider PM. TaqMan low-density arrays and analysis by artificial neuronal networks predict response to neoadjuvant chemoradiation in esophageal cancer. Pharmacogenomics. 2010;11:55-64. [PMID: 20017672 DOI: 10.2217/pgs.09.137] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
167 Lee JM, Yang SY, Yang PW, Shun CT, Wu MT, Hsu CH, Lin CC, Cheng JC, Wang YH, Chuang TH, Chen JS, Hsu HH, Huang PM, Kuo SW, Lee YC. Polymorphism in epidermal growth factor receptor intron 1 predicts prognosis of patients with esophageal cancer after chemoradiation and surgery. Ann Surg Oncol 2011;18:2066-73. [PMID: 21298351 DOI: 10.1245/s10434-011-1559-9] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
168 Ling FC, Hoelscher AH, Vallböhmer D, Schmidt D, Picker S, Gathof BS, Bollschweiler E, Schneider PM. Leukocyte depletion in allogeneic blood transfusion does not change the negative influence on survival following transthoracic resection for esophageal cancer. J Gastrointest Surg. 2009;13:581-586. [PMID: 19152023 DOI: 10.1007/s11605-008-0787-1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
169 van Hagen P, Wijnhoven BP, Nafteux P, Moons J, Haustermans K, De Hertogh G, van Lanschot JJ, Lerut T. Recurrence pattern in patients with a pathologically complete response after neoadjuvant chemoradiotherapy and surgery for oesophageal cancer. Br J Surg 2013;100:267-73. [PMID: 23180560 DOI: 10.1002/bjs.8968] [Cited by in Crossref: 55] [Cited by in F6Publishing: 44] [Article Influence: 6.1] [Reference Citation Analysis]
170 Narumiya K, Metzger R, Bollschweiler E, Alakus H, Brabender J, Drebber U, Hölscher AH, Warnecke-Eberz U. Impact of ABCB1 C3435T polymorphism on lymph node regression in multimodality treatment of locally advanced esophageal cancer. Pharmacogenomics 2011;12:205-14. [PMID: 21332314 DOI: 10.2217/pgs.10.174] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
171 Lin G, Lin KJ, Wang F, Chen TC, Yen TC, Yeh TS. Synergistic antiproliferative effects of an mTOR inhibitor (rad001) plus gemcitabine on cholangiocarcinoma by decreasing choline kinase activity. Dis Model Mech 2018;11:dmm033050. [PMID: 29666220 DOI: 10.1242/dmm.033050] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
172 Brücher BLDM, Swisher SG, Königsrainer A, Zieker D, Hartmann J, Stein H, Kitagawa Y, Law S, Ajani JA. Response to Preoperative Therapy in Upper Gastrointestinal Cancers. Ann Surg Oncol 2009;16:878-86. [DOI: 10.1245/s10434-009-0315-x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
173 Tong Y, Zhu Y, Zhao Y, Shan Z, Liu D, Zhang J. Evaluation and Comparison of Predictive Value of Tumor Regression Grades according to Mandard and Becker in Locally Advanced Gastric Adenocarcinoma. Cancer Res Treat 2021;53:112-22. [PMID: 32777876 DOI: 10.4143/crt.2020.516] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
174 Becker K, Reim D, Novotny A, Zum Büschenfelde CM, Engel J, Friess H, Höfler H, Langer R. Proposal for a multifactorial prognostic score that accurately classifies 3 groups of gastric carcinoma patients with different outcomes after neoadjuvant chemotherapy and surgery. Ann Surg. 2012;256:1002-1007. [PMID: 22968067 DOI: 10.1097/sla.0b013e318262a591] [Cited by in Crossref: 32] [Cited by in F6Publishing: 22] [Article Influence: 4.0] [Reference Citation Analysis]
175 Semrau R, Herzog SL, Vallböhmer D, Kocher M, Hölscher AH, Müller RP. Prognostic factors in definitive radiochemotherapy of advanced inoperable esophageal cancer. Dis Esophagus 2012;25:545-54. [PMID: 22133297 DOI: 10.1111/j.1442-2050.2011.01286.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
176 Kauppi JT, Oksala N, Salo JA, Helin H, Karhumäki L, Kemppainen J, Sihvo EI, Räsänen JV. Locally advanced esophageal adenocarcinoma: response to neoadjuvant chemotherapy and survival predicted by ([18F])FDG-PET/CT. Acta Oncol. 2012;51:636-644. [PMID: 22208782 DOI: 10.3109/0284186X.2011.643822] [Cited by in Crossref: 17] [Cited by in F6Publishing: 5] [Article Influence: 1.9] [Reference Citation Analysis]
177 Bollschweiler E, Besch S, Drebber U, Schröder W, Mönig SP, Vallböhmer D, Baldus SE, Metzger R, Hölscher AH. Influence of neoadjuvant chemoradiation on the number and size of analyzed lymph nodes in esophageal cancer. Ann Surg Oncol 2010;17:3187-94. [PMID: 20585867 DOI: 10.1245/s10434-010-1196-8] [Cited by in Crossref: 32] [Cited by in F6Publishing: 21] [Article Influence: 2.9] [Reference Citation Analysis]
178 Brabender J, Vallböhmer D, Grimminger P, Hoffmann AC, Ling F, Lurje G, Bollschweiler E, Schneider PM, Hölscher AH, Metzger R. ERCC1 RNA expression in peripheral blood predicts minor histopathological response to neoadjuvant radio-chemotherapy in patients with locally advanced cancer of the esophagus. J Gastrointest Surg. 2008;12:1815-1821. [PMID: 18769985 DOI: 10.1007/s11605-008-0668-7] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 2.1] [Reference Citation Analysis]
179 Burmeister BH, Thomas JM, Burmeister EA, Walpole ET, Harvey JA, Thomson DB, Barbour AP, Gotley DC, Smithers BM. Is concurrent radiation therapy required in patients receiving preoperative chemotherapy for adenocarcinoma of the oesophagus? A randomised phase II trial. Eur J Cancer. 2011;47:354-360. [PMID: 21084184 DOI: 10.1016/j.ejca.2010.09.009] [Cited by in Crossref: 184] [Cited by in F6Publishing: 141] [Article Influence: 18.4] [Reference Citation Analysis]
180 Schröder W, Hölscher AH, Bludau M, Vallböhmer D, Bollschweiler E, Gutschow C. Ivor-Lewis esophagectomy with and without laparoscopic conditioning of the gastric conduit. World J Surg 2010;34:738-43. [PMID: 20098986 DOI: 10.1007/s00268-010-0403-x] [Cited by in Crossref: 77] [Cited by in F6Publishing: 56] [Article Influence: 7.0] [Reference Citation Analysis]
181 Blank S, Stange A, Sisic L, Roth W, Grenacher L, Sterzing F, Burian M, Jäger D, Büchler M, Ott K. Preoperative therapy of esophagogastric cancer: the problem of nonresponding patients. Langenbecks Arch Surg 2013;398:211-20. [PMID: 23224565 DOI: 10.1007/s00423-012-1034-5] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
182 Drebber U, Madeja M, Odenthal M, Wedemeyer I, Mönig SP, Brabender J, Bollschweiler E, Hölscher AH, Schneider PM, Dienes HP, Vallböhmer D. β-catenin and Her2/neu expression in rectal cancer: association with histomorphological response to neoadjuvant therapy and prognosis. Int J Colorectal Dis 2011;26:1127-34. [DOI: 10.1007/s00384-011-1213-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
183 Mehta SP, Jose P, Mirza A, Pritchard SA, Hayden JD, Grabsch HI. Comparison of the prognostic value of the 6th and 7th editions of the Union for International Cancer Control TNM staging system in patients with lower esophageal cancer undergoing neoadjuvant chemotherapy followed by surgery: Comparison of UICC TNM staging systems. Dis Esophagus 2013;26:182-8. [DOI: 10.1111/j.1442-2050.2012.01350.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
184 He W, Mao T, Yan J, Leng X, Deng X, Xie Q, Peng L, Liao Q, Scarpa M, Han Y. Moderately differentiated esophageal squamous cell carcinoma has a poor prognosis after neoadjuvant chemoradiotherapy. Ann Transl Med 2021;9:706. [PMID: 33987404 DOI: 10.21037/atm-21-1815] [Reference Citation Analysis]
185 Vallböhmer D, Brabender J, Grimminger P, Schröder W, Hölscher AH. Predicting response to neoadjuvant therapy in esophageal cancer. Expert Review of Anticancer Therapy 2014;11:1449-55. [DOI: 10.1586/era.11.126] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
186 Zingg U, Forberger J, Rajcic B, Langton C, Jamieson GG. Association of C-Reactive Protein Levels and Long-Term Survival after Neoadjuvant Therapy and Esophagectomy for Esophageal Cancer. J Gastrointest Surg 2010;14:462-9. [DOI: 10.1007/s11605-009-1113-2] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 2.2] [Reference Citation Analysis]
187 Lindner K, Borchardt C, Schöpp M, Bürgers A, Stock C, Hussey DJ, Haier J, Hummel R. Proton pump inhibitors (PPIs) impact on tumour cell survival, metastatic potential and chemotherapy resistance, and affect expression of resistance-relevant miRNAs in esophageal cancer. J Exp Clin Cancer Res. 2014;33:73. [PMID: 25175076 DOI: 10.1186/s13046-014-0073-x] [Cited by in Crossref: 43] [Cited by in F6Publishing: 32] [Article Influence: 6.1] [Reference Citation Analysis]
188 Vallböhmer D, Hölscher AH, Herbold T, Gutschow C, Schröder W. Diaphragmatic Hernia After Conventional or Laparoscopic-Assisted Transthoracic Esophagectomy. The Annals of Thoracic Surgery 2007;84:1847-52. [DOI: 10.1016/j.athoracsur.2007.07.009] [Cited by in Crossref: 51] [Cited by in F6Publishing: 31] [Article Influence: 3.6] [Reference Citation Analysis]
189 Thies S, Langer R. Tumor regression grading of gastrointestinal carcinomas after neoadjuvant treatment. Front Oncol. 2013;3:262. [PMID: 24109590 DOI: 10.3389/fonc.2013.00262] [Cited by in Crossref: 70] [Cited by in F6Publishing: 55] [Article Influence: 8.8] [Reference Citation Analysis]
190 Plum PS, Damanakis A, Buschmann L, Ernst A, Datta RR, Schiffmann LM, Zander T, Fuchs H, Chon SH, Alakus H, Schröder W, Hölscher AH, Bruns CJ, Bludau M. Short-term outcome of Ivor Lewis esophagectomy following neoadjuvant chemoradiation versus perioperative chemotherapy in patients with locally advanced adenocarcinoma of the esophagus and gastroesophageal junction: a propensity score-matched analysis. J Cancer Res Clin Oncol 2021. [PMID: 34223965 DOI: 10.1007/s00432-021-03720-5] [Reference Citation Analysis]
191 Zanoni A. Nodal downstaging in esophageal and esophagogastric junction cancer: more important than ever. J Thorac Dis 2017;9:1839-42. [PMID: 28839979 DOI: 10.21037/jtd.2017.06.126] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
192 Findlay JM, Bradley KM, Wang LM, Franklin JM, Teoh EJ, Gleeson FV, Maynard ND, Gillies RS, Middleton MR. Metabolic nodal response as a prognostic marker after neoadjuvant therapy for oesophageal cancer. British Journal of Surgery 2017;104:408-17. [DOI: 10.1002/bjs.10435] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
193 Wang X, Wang H, Wang H, Huang J, Wang X, Jiang Z, Tan L, Jiang D, Hou Y. Prognostic value of visual residual tumour cells (VRTC) for patients with esophageal squamous cell carcinomas after neoadjuvant therapy followed by surgery. BMC Cancer 2021;21:111. [PMID: 33535987 DOI: 10.1186/s12885-020-07779-0] [Reference Citation Analysis]
194 Soror T, Kho G, Zhao KL, Ismail M, Badakhshi H. Impact of pathological complete response following neoadjuvant chemoradiotherapy in esophageal cancer. J Thorac Dis 2018;10:4069-76. [PMID: 30174850 DOI: 10.21037/jtd.2018.06.85] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
195 Metzger R, Heukamp L, Drebber U, Bollschweiler E, Zander T, Hoelscher AH, Warnecke-Eberz U. CUL2 and STK11 as novel response-predictive genes for neoadjuvant radiochemotherapy in esophageal cancer. Pharmacogenomics. 2010;11:1105-1113. [PMID: 20712528 DOI: 10.2217/pgs.10.76] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
196 Kadota T, Hatogai K, Yano T, Fujita T, Kojima T, Daiko H, Fujii S. Pathological tumor regression grade of metastatic tumors in lymph node predicts prognosis in esophageal cancer patients. Cancer Sci 2018;109:2046-55. [PMID: 29601131 DOI: 10.1111/cas.13596] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
197 Wedemeyer I, Kreppel M, Scheer M, Zöller J, Büttner R, Drebber U. Histopathological assessment of tumour regression, nodal stage and status of resection margins determines prognosis in patients with oral squamous cell carcinoma treated with neoadjuvant radiochemotherapy. Oral Dis 2014;20:e81-9. [DOI: 10.1111/odi.12137] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.9] [Reference Citation Analysis]
198 Gutschow CA, Hölscher AH, Leers J, Fuchs H, Bludau M, Prenzel KL, Bollschweiler E, Schröder W. Health-related quality of life after Ivor Lewis esophagectomy. Langenbecks Arch Surg. 2013;398:231-237. [PMID: 22661100 DOI: 10.1007/s00423-012-0960-6] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
199 Brücher B. Plattenepithelkarzinom des Ösophagus: Präoperative kombinierte Radiochemotherapie aus chirurgisch-onkologischer Sicht. Chirurg 2009;80:1011-8. [DOI: 10.1007/s00104-009-1733-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
200 Miyata H, Yoshioka A, Yamasaki M, Nushijima Y, Takiguchi S, Fujiwara Y, Nishida T, Mano M, Mori M, Doki Y. Tumor budding in tumor invasive front predicts prognosis and survival of patients with esophageal squamous cell carcinomas receiving neoadjuvant chemotherapy. Cancer. 2009;115:3324-3334. [PMID: 19452547 DOI: 10.1002/cncr.24390] [Cited by in Crossref: 74] [Cited by in F6Publishing: 72] [Article Influence: 6.2] [Reference Citation Analysis]
201 Wang C, Cheng JC, Tsai C, Lee J, Huang P, Lin C, Hsu C, Hsieh M, Chang Y, Hsu F. Pathological stage after neoadjuvant chemoradiation and esophagectomy superiorly predicts survival in patients with esophageal squamous cell carcinoma. Radiotherapy and Oncology 2015;115:9-15. [DOI: 10.1016/j.radonc.2015.03.019] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
202 Hatogai K, Fujii S, Kojima T, Daiko H, Kadota T, Fujita T, Yoshino T, Doi T, Takiguchi Y, Ohtsu A. Prognostic significance of tumor regression grade for patients with esophageal squamous cell carcinoma after neoadjuvant chemotherapy followed by surgery. J Surg Oncol 2016;113:390-6. [PMID: 27100024 DOI: 10.1002/jso.24151] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
203 Okumura H, Uchikado Y, Matsumoto M, Owaki T, Kita Y, Omoto I, Sasaki K, Sakurai T, Setoyama T, Nabeki B, Matsushita D, Ishigami S, Hiraki Y, Nakajo M, Natsugoe S. Prognostic factors in esophageal squamous cell carcinoma patients treated with neoadjuvant chemoradiation therapy. Int J Clin Oncol 2013;18:329-34. [PMID: 22350023 DOI: 10.1007/s10147-012-0383-y] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
204 Donahue JM, Nichols FC, Li Z, Schomas DA, Allen MS, Cassivi SD, Jatoi A, Miller RC, Wigle DA, Shen KR, Deschamps C. Complete pathologic response after neoadjuvant chemoradiotherapy for esophageal cancer is associated with enhanced survival. Ann Thorac Surg 2009;87:392-8; discussion 398-9. [PMID: 19161745 DOI: 10.1016/j.athoracsur.2008.11.001] [Cited by in Crossref: 179] [Cited by in F6Publishing: 145] [Article Influence: 14.9] [Reference Citation Analysis]
205 O'Neill JR, Kennedy ED, Save V, Langdale-Brown B, Wall L, Skipworth RJE, Paterson-Brown S. Patients unfit for neoadjuvant therapy may still undergo resection of locally advanced esophageal or esophagogastric junctional cancer with acceptable oncological results. Int J Surg Oncol (N Y) 2017;2:e09. [PMID: 29177210 DOI: 10.1097/IJ9.0000000000000009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
206 Metzger R, Drebber U, Baldus SE, Mönig SP, Hölscher AH, Bollschweiler E. Extracapsular Lymph Node Involvement Differs Between Squamous Cell and Adenocarcinoma of the Esophagus. Ann Surg Oncol 2009;16:447-53. [DOI: 10.1245/s10434-008-0248-9] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 2.1] [Reference Citation Analysis]